Nothing said here yet.
to join the conversation.
Evotec’s latest announcement landed hard. Management cut its 2026 revenue and EBITDA guidance after partnership milestones slipped, then reported weaker Q2 2026 figures with a deeper net loss.
UAE residents can spot the ultra-thin 9 mm True Wireless OLED evo W6 at iconic destinations across the country, with interactive social contests and a chance to win the flagship television.
Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of global experience in pharma, biotechnology and academia…
Investing.com -- Evotec shares jumped about 7% in Frankfurt trading after the German drug discovery company said preliminary nine-month results topped market expectations. It also reaffirmed its full-year 2026 guidance.
Dr. Cord Dohrmann to step down as of September 30, 2026 Search ongoing for a successor HAMBURG, Germany, Sept.
Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept.
Pharma companies are expanding drug discovery outsourcing to cut costs, access CRO expertise and AI tools, speed pipelines, manage regulatory complexity, and advance targeted therapies.Dublin, Sept.
AI-driven screening, advanced imaging and demand for targeted therapies are accelerating FBDD, creating opportunities in oncology, neurology and traditionally undruggable targets.Dublin, Sept.
Automation, robotics, AI, cloud platforms and RFID are transforming compound management, creating opportunities in drug discovery, biotech, materials science and distributed research.Dublin, Sept.